MX2023008375A - Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas. - Google Patents

Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas.

Info

Publication number
MX2023008375A
MX2023008375A MX2023008375A MX2023008375A MX2023008375A MX 2023008375 A MX2023008375 A MX 2023008375A MX 2023008375 A MX2023008375 A MX 2023008375A MX 2023008375 A MX2023008375 A MX 2023008375A MX 2023008375 A MX2023008375 A MX 2023008375A
Authority
MX
Mexico
Prior art keywords
subject
methods
pharmaceutical compositions
breast cancers
treating breast
Prior art date
Application number
MX2023008375A
Other languages
English (en)
Spanish (es)
Inventor
James Dalton
Sunjoo Ahn
Ramesh Narayanan
Mitchell STEINER
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US12685719B2/en
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of MX2023008375A publication Critical patent/MX2023008375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023008375A 2021-01-15 2022-01-14 Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas. MX2023008375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/151,108 US12685719B2 (en) 2012-07-13 2021-01-15 Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (1)

Publication Number Publication Date
MX2023008375A true MX2023008375A (es) 2023-10-05

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008375A MX2023008375A (es) 2021-01-15 2022-01-14 Composiciones farmacéuticas para tratar cánceres de mama y métodos de usos de estas.

Country Status (10)

Country Link
EP (1) EP4277613A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024503718A (cg-RX-API-DMAC7.html)
KR (1) KR20230163362A (cg-RX-API-DMAC7.html)
CN (1) CN116981451A (cg-RX-API-DMAC7.html)
AU (1) AU2022208712A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014247A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205212A1 (cg-RX-API-DMAC7.html)
IL (1) IL304467A (cg-RX-API-DMAC7.html)
MX (1) MX2023008375A (cg-RX-API-DMAC7.html)
WO (1) WO2022155543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (zh) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 丙酰胺类雄激素受体拮抗剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US10314807B2 (en) * 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3733170A1 (en) * 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
WO2017223115A1 (en) * 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders

Also Published As

Publication number Publication date
BR112023014247A2 (pt) 2023-10-03
KR20230163362A (ko) 2023-11-30
WO2022155543A1 (en) 2022-07-21
JP2024503718A (ja) 2024-01-26
CA3205212A1 (en) 2022-07-21
IL304467A (en) 2023-09-01
EP4277613A4 (en) 2024-11-20
EP4277613A1 (en) 2023-11-22
AU2022208712A9 (en) 2024-09-19
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31

Similar Documents

Publication Publication Date Title
ZA201907225B (en) Treatment of her2 positive cancers
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
PH12018500642A1 (en) Anti-garp antibody
EA202190749A1 (ru) Способы комбинированной терапии
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
PT1255537E (pt) Inibidores da proteina farnesil transferase para tratar cancro da mama
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
BR112023014247A2 (pt) Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas
PH12020500666A1 (en) Pladienolide compounds and their use
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
EA202192757A1 (ru) Способ лечения опухолей
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
MX2022011646A (es) Celulas t v delta1+ para el tratamiento de neoplasias mieloides.
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
MX2025013034A (es) Inhibidores de egfr para el tratamiento de enfermedades
EA202092861A1 (ru) Специфичные в отношении злокачественной опухоли t-клеточные рецепторы
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.